Adrenocortical Carcinoma - Pipeline Insight, 2021
![](/report_cover/8047/adrenocortical-carcinoma-pipeline-insight-2020_en.gif)
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “Adrenocortical Carcinoma - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Adrenocortical Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Adrenocortical Carcinoma: Overview
Adrenal cortical carcinoma (ACC) is a rare disease. It is caused by a cancerous growth in the adrenal cortex, which is the outer layer of the adrenal glands. The adrenal glands lie on top of the kidneys. They play an important role in the endocrine system, which is the system that produces and regulates hormones. ACC is also known as adrenocortical carcinoma. The adrenal cortex makes hormones that regulate metabolism and blood pressure. It also produces cortisol and the male hormones called androgens, such as testosterone. ACC may trigger excessive production of these hormones.
'Adrenocortical Carcinoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Adrenocortical Carcinoma pipeline landscape is provided which includes the disease overview and Adrenocortical Carcinoma treatment guidelines. The assessment part of the report embraces, in depth Adrenocortical Carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Adrenocortical Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Adrenocortical Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Adrenocortical Carcinoma Emerging Drugs
Further product details are provided in the report……..
Adrenocortical Carcinoma: Therapeutic Assessment
This segment of the report provides insights about the different Adrenocortical Carcinoma drugs segregated based on following parameters that define the scope of the report, such as:
Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
Adrenocortical Carcinoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Adrenocortical Carcinoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Adrenocortical Carcinoma drugs.
Adrenocortical Carcinoma Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Adrenocortical Carcinoma - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Adrenocortical Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Adrenocortical Carcinoma: Overview
Adrenal cortical carcinoma (ACC) is a rare disease. It is caused by a cancerous growth in the adrenal cortex, which is the outer layer of the adrenal glands. The adrenal glands lie on top of the kidneys. They play an important role in the endocrine system, which is the system that produces and regulates hormones. ACC is also known as adrenocortical carcinoma. The adrenal cortex makes hormones that regulate metabolism and blood pressure. It also produces cortisol and the male hormones called androgens, such as testosterone. ACC may trigger excessive production of these hormones.
'Adrenocortical Carcinoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Adrenocortical Carcinoma pipeline landscape is provided which includes the disease overview and Adrenocortical Carcinoma treatment guidelines. The assessment part of the report embraces, in depth Adrenocortical Carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Adrenocortical Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Adrenocortical Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve Adrenocortical Carcinoma.
This segment of the Adrenocortical Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Adrenocortical Carcinoma Emerging Drugs
- Relacorilant: Corcept Therapeutics
- Ipilimumab: Bristol-Myers Squibb
Further product details are provided in the report……..
Adrenocortical Carcinoma: Therapeutic Assessment
This segment of the report provides insights about the different Adrenocortical Carcinoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Adrenocortical Carcinoma
Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
- Late-stage products (phase III)
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Subcutaneous
- Intravenous
- Oral
- Intramuscular
- Molecule Type
- Small molecules
- Natural metabolites
- Monoclonal antibodies
- Product Type
Adrenocortical Carcinoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Adrenocortical Carcinoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Adrenocortical Carcinoma drugs.
Adrenocortical Carcinoma Report Insights
- Adrenocortical Carcinoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Adrenocortical Carcinoma drugs?
- How many Adrenocortical Carcinoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Adrenocortical Carcinoma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Adrenocortical Carcinoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Adrenocortical Carcinoma and their status?
- What are the key designations that have been granted to the emerging drugs?
- Corcept Therapeutics
- Bristol-Myers Squibb
- Enterome
- Exelixis/Ipsen
- Genentech
- Relacorilant
- Ipilimumab
- EO 2401
- Cabozantinib
- Atezolizumab
Introduction
Executive Summary
Adrenocortical Carcinoma: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Adrenocortical Carcinoma – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Adrenocortical Carcinoma companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Adrenocortical Carcinoma Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
• Comparative Analysis
Ipilimumab: Bristol-Myers Squibb
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
Relacorilant: Corcept Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Adrenocortical Carcinoma Key Companies
Adrenocortical Carcinoma Key Products
Adrenocortical Carcinoma- Unmet Needs
Adrenocortical Carcinoma- Market Drivers and Barriers
Adrenocortical Carcinoma- Future Perspectives and Conclusion
Adrenocortical Carcinoma Analyst Views
Adrenocortical Carcinoma Key Companies
Appendix
Executive Summary
Adrenocortical Carcinoma: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Adrenocortical Carcinoma – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Adrenocortical Carcinoma companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Adrenocortical Carcinoma Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
• Comparative Analysis
Ipilimumab: Bristol-Myers Squibb
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
Relacorilant: Corcept Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Adrenocortical Carcinoma Key Companies
Adrenocortical Carcinoma Key Products
Adrenocortical Carcinoma- Unmet Needs
Adrenocortical Carcinoma- Market Drivers and Barriers
Adrenocortical Carcinoma- Future Perspectives and Conclusion
Adrenocortical Carcinoma Analyst Views
Adrenocortical Carcinoma Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Adrenocortical Carcinoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Adrenocortical Carcinoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Adrenocortical Carcinoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Adrenocortical Carcinoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products